Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osmotic dilators vs. Foley balloons: Bayesian secondary analyses of the DILAFOL trial.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2026
Same author

Parenteral Lipid Dose and Bilirubin Neurotoxicity in Extremely Preterm Infants: A Factorial Randomized Trial.

The Journal of pediatrics·2026
Same author

Determinants of body mass index in early systemic sclerosis: implications for nutritional risk stratification.

Arthritis care & research·2026
Same author

Glucose circadian rhythm disruption is associated with preeclampsia.

Chronobiology international·2026
Same author

Early gastrointestinal manifestations predict disease progression and mortality in patients with systemic sclerosis.

Rheumatology (Oxford, England)·2026
Same author

Autologous adipose-derived mesenchymal stromal cells for chronic traumatic brain injury.

Brain : a journal of neurology·2026

Related Experiment Video

Updated: Apr 18, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

138.1K

Antinuclear antibody-negative systemic sclerosis.

Gloria A Salazar1, Shervin Assassi1, Fredrick Wigley2

  • 1Division of Rheumatology, University of Texas Medical School at Houston, 6431 Fannin St. MSB 5.270, Houston, TX 77030.

Seminars in Arthritis and Rheumatism
|January 13, 2015
PubMed
Summary
This summary is machine-generated.

Systemic sclerosis (SSc) patients without antinuclear antibodies (ANA) are a distinct group, showing less vasculopathy like pulmonary arterial hypertension and digital ulcers, but more gastrointestinal issues. This ANA-negative subset also has a higher male proportion.

Keywords:
ANAAntinuclear antibodyNegativeSclerodermaSystemic sclerosisVasculopathy

More Related Videos

Isolation of Double Negative αβ T Cells from the Kidney
06:56

Isolation of Double Negative αβ T Cells from the Kidney

Published on: May 16, 2014

12.9K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.7K

Related Experiment Videos

Last Updated: Apr 18, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

138.1K
Isolation of Double Negative αβ T Cells from the Kidney
06:56

Isolation of Double Negative αβ T Cells from the Kidney

Published on: May 16, 2014

12.9K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.7K

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic sclerosis (SSc) is a complex autoimmune disease characterized by fibrosis, vasculopathy, and immune dysregulation.
  • Antinuclear antibodies (ANA) are common in SSc, but a subset of patients are ANA-negative, whose distinct characteristics are not well-defined.

Purpose of the Study:

  • To investigate the demographic and clinical differences between ANA-negative and ANA-positive patients with systemic sclerosis.
  • To identify potential unique features of the ANA-negative SSc subset for improved understanding and management.

Main Methods:

  • Analysis of data from 3249 SSc patients in the Scleroderma Family Registry and DNA Repository.
  • Comparison of demographic and clinical features, including antibody status, organ involvement, and mortality, between ANA-negative (n=208) and ANA-positive patients.

Main Results:

  • ANA-negative SSc patients had a higher proportion of males (OR=1.65) and experienced less vasculopathic manifestations, including lower prevalence of pulmonary arterial hypertension (PAH) (OR=0.28), telangiectasias (OR=0.59), and digital ulcers (OR=0.38).
  • ANA-negative patients showed higher diffusing capacity of carbon monoxide (DLCO) (p=0.03), lower modified Rodnan Skin Score (mRSS) (p=0.05), and more frequent malabsorption (p=0.05).
  • No significant differences were observed in pulmonary fibrosis, scleroderma renal crisis, or all-cause mortality between the groups.

Conclusions:

  • ANA-negative SSc patients represent a distinct clinical subset characterized by reduced vasculopathy, a higher male prevalence, and potentially increased gastrointestinal involvement.
  • These findings highlight the heterogeneity within SSc and the importance of considering antibody status in patient characterization.